Search Results

Displaying Results 2201-2225 of 10857 "'T'"

Jun 30, 2026, 09:00 ET Crunch Franchise Brings State-of-the-Art Crunch 3.0 Gym to Leander, Texas

members will join for only $1 and get their first month free plus get a free one hour personal training session and a free gym bag, water bottle and t-shirt. You can enter to win a free year long all access membership and lock in your Founding 500 rate at

More news about: Crunch Fitness


Jun 30, 2026, 08:50 ET Education Couture Launches $100,000 Summer Lux Learner Unlock Event to Keep Students Engaged in Learning

activities.As students accumulate points, they unlock access to premium Lux Learner apparel releases while supplies last. The collection includes T-shirts, hoodies, cardigans, and limited-edition garments with retail values reaching into the hundreds of dollars."These rewards represent more than

More news about: Education Couture


Jun 30, 2026, 08:33 ET Horvath & Tremblay Acquires SCOPE, Expanding its National CRE Platform Deeper into the Mid-Atlantic

and broker support model. Most recently, H&T acquired B6, a NYC-based brokerage led by Paul Massey. H&T will be announcing its new NYC office in the coming weeks with approximately 6,000 square feet adjacent to Bryant Park.In 2025, H&T further broadened its capabilities from investment

More news about: Horvath & Tremblay


Jun 30, 2026, 08:03 ET Bell Integration will join NiCE 1-2 July 2026 at NiCE World London

summarisation.Media contactFinola Sloyan | E [email protected] | T +44 2392 825925About NiCENiCE (NASDAQ: NICE) is transforming the

More news about: Bell Integration


Jun 30, 2026, 07:15 ET ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial

and Part 2 (dose expansion). The three dosing arms include ZYNLONTA plus polatuzumab vedotin, ZYNLONTA plus glofitamab, and ZYNLONTA plus mosunetuzumab T-cell-engaging bispecific monoclonal antibodies (BsAbs). Enrollment in LOTIS-7 includes Part 1 of the study with a 3+3 dose escalation in 3L+ heavily pre-treated

More news about: ADC Therapeutics SA


Jun 30, 2026, 07:05 ET MSC Income Fund Announces CEO Succession Plan

Dwayne L. Hyzak to Remain Executive Chairman as Nicholas T. Meserve Becomes CEO in the Fourth Quarter of 2026HOUSTON, June 30, 2026 /PRNewswire/ -- MSC Income Fund, Inc. (NYSE: MSIF) ("MSC

More news about: MSC Income Fund, Inc.


Jun 30, 2026, 07:00 ET AT&T Expands Build-A-Plan: Flexible Custom Wireless Plan Now Includes the Ability to Easily Add America's Best and Fastest Home Internet

home internet connection.What is AT&T Internet Air?AT&T Internet Air is our wireless home internet delivered over the reliable AT&T 5G network.7What is the difference between AT&T OneConnect and Build-A-Plan?Both offer

More news about: AT&T


Jun 30, 2026, 06:21 ET $GIL Notification: Gildan Investigated for Misrepresentations about its Revenue Sources after 18% Stock Drop

Gildan's stock price caused significant losses to investors.Gildan is an apparel manufacturer that produces and sells basic clothing—such as T‑shirts, fleece, underwear, and socks—primarily in bulk to wholesalers, screen printers, and retailers.BFA is investigating whether Gildan misled investors

More news about: Bleichmar Fonti & Auld LLP


Jun 30, 2026, 05:43 ET Beyond Folding Bikes at EUROBIKE 2026 - DAHON Charts the Future of Green Mobility

also marked the international debut of BICECO by DAHON.Voice on the Industry's FutureDAHON Founder and CEO Dr. David T. Hon was interviewed by major European cycling media, including BikeBiz, BikeRadar, ELECTRIC BIKE, and Velo 101. He outlined the engineering

More news about: DAHON TECH


Jun 30, 2026, 05:37 ET METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager

by Deerfield Management, granting Boulevard worldwide development, manufacturing, and commercialization rights for MTS-128, a proprietary trispecific T-cell engager (TCE) program developed by METiS TechBio.

More news about: METiS TechBio


Jun 30, 2026, 05:08 ET Bratz® and Rodarte Introduce a Fashion Collaboration Featuring Coveted Collector Dolls and Exclusive Apparel

creating a unique designer fashion moment for fans and collectors. Featuring Sasha and Cloe, the assortment includes Rodarte baby tees, a graphic T-shirt, and a crewneck sweatshirt.As Bratz continues its milestone 25th anniversary celebration, the Rodarte collaboration further reinforces the brand's

More news about: MGA Entertainment


Jun 30, 2026, 04:00 ET MIMARU Highlights How International Travelers Are Turning Japan's Marathons into Family Holidays

https://drive.google.com/file/d/1uU8l3WFZ5emHiqGYMm9R7bhHumuIWL6T/view?usp=sharing https://kyoto-marathon.com/en/

More news about: Cosmos Hotel Management Co., Ltd.


Jun 30, 2026, 03:11 ET Roca Introduces Touch-T: A New Benchmark in Thermostatic Shower Systems

Touch-T, its most intuitive thermostatic shower system to date. Conceived around the philosophy of minimalist elegance, Touch-T strips away the complexity of conventional shower controls to deliver an exceptional

More news about: Roca India


Jun 30, 2026, 03:03 ET Bell Integration will join NiCE 1-2 July 2026 at NiCE World London

summarisation.Media contactFinola Sloyan | E [email protected] | T +44 2392 825925About NiCENiCE (NASDAQ: NICE) is transforming the

More news about: Bell Integration


Jun 30, 2026, 02:03 ET Bell Integration participará en NiCE World London del 1 al 2 de julio de 2026

automatizado.Contacto de medios Finola Sloyan | E [email protected] | T +44 2392 825925Acerca de NiCE NiCE (NASDAQ: NICE) está transformando

More news about: Bell Integration


Jun 30, 2026, 00:03 ET Bell Integration will join NiCE 1-2 July 2026 at NiCE World London

summarisation.Media contactFinola Sloyan | E [email protected] | T +44 2392 825925About NiCENiCE (NASDAQ: NICE) is transforming the

More news about: Bell Integration


Jun 30, 2026, 00:03 ET Bell Integration will join NiCE 1-2 July 2026 at NiCE World London

summarisation.Media contactFinola Sloyan | E [email protected] | T +44 2392 825925About NiCENiCE (NASDAQ: NICE) is transforming the

More news about: Bell Integration


Jun 29, 2026, 18:18 ET /C O R R E C T I O N -- TrackVia/

More news about: TrackVia


Jun 29, 2026, 18:03 ET /C O R R E C T I O N -- RoarFun™/

More news about: RoarFun™


Jun 29, 2026, 18:01 ET AFTER RECEIVING SUPPORT FROM TWO PROXY ADVISORS, TOBY NEUGEBAUER TO HOST TOWN HALL WEBINAR TOMORROW, JUNE 30 AT 4PM ET, TAKING LIVE, UNSCRIPTED QUESTIONS FROM ANALYSTS

Management LLC and Melissa A. Neugebauer 2020 Trust (collectively with Mr. Neugebauer, the "Fermi Founder Parties"), David A. Daglio, Charles M. Elson, John T. Jimenez, Janet Yang, Sheila Hooda and Juan A. Pujadas (collectively, the "Participants") have filed a definitive proxy statement on Schedule 14A, accompanying

More news about: Toby Neugebauer


Jun 29, 2026, 17:41 ET /C O R R E C T I O N -- Blue Ivy Partners/

More news about: Blue Ivy Partners


Jun 29, 2026, 17:32 ET AFTER RECEIVING SUPPORT FROM TWO PROXY ADVISORS, TOBY NEUGEBAUER TO HOST TOWN HALL WEBINAR TOMORROW, JUNE 30 AT 4PM ET, TAKING LIVE, UNSCRIPTED QUESTIONS FROM ANALYSTS

Management LLC and Melissa A. Neugebauer 2020 Trust (collectively with Mr. Neugebauer, the "Fermi Founder Parties"), David A. Daglio, Charles M. Elson, John T. Jimenez, Janet Yang, Sheila Hooda and Juan A. Pujadas (collectively, the "Participants") have filed a definitive proxy statement on Schedule 14A, accompanying

More news about: Toby Neugebauer


Jun 29, 2026, 16:52 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.1Epcoritamab

More news about: AbbVie


Jun 29, 2026, 16:15 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.1Epcoritamab

More news about: AbbVie


Jun 29, 2026, 14:57 ET /C O R R E C T I O N -- Duck® Brand/

/C O R R E C T I O N – Duck® Brand/ In the news release, VOTING NOW OPEN FOR 2026 STUCK AT PROM® SCHOLARSHIP CONTEST AS DUCK® BRAND UNVEILS TOP 10 STUDENT FINALISTS, issued 29-Jun-2026 by Duck® Brand over PR Newswire, we are advised by the company that changes have been made. The complete, corrected

More news about: Duck® Brand


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.